Heart FailurePhase 1NCT04722484
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants
A Phase 1 study testing Vericiguat (BAY1021189) in people with Heart Failure, run by Bayer at 1 site in Germany.
Trial summary
Vericiguat (BAY1021189) is under development to treat heart failure, a condition in in which the heart has trouble pumping blood through the body. Renal impairment which co-occurs in patients with heart failure is a common condition in which the kidneys are not filtering the blood as well as they should. Read more about this study
- Who is it for?
- Ages 18 to 79 yearsHealthy volunteers can take part
- Conditions the study is for
- Heart Failure
- What is being tested?
- Vericiguat (BAY1021189)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 39 participants
- Where
- 1 siteGermany
- Study dates
- 12 Jun 2014to 22 Jan 2015
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 79 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- For all subjects:
- Aged between 18 and 79 years (inclusive) with body mass index 18 to 34 kg/m^2 (both inclusive)
- Women without childbearing potential; women of childbearing potential only if the pregnancy test was negative and a combination of condoms with a safe and highly effective contraception method was granted
- For subjects with renal impairment:
- With an estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73m^2 determined from a serum creatinine control 2-14 days prior to dosing
- Stable renal disease, i.e. a serum creatinine value determined at least 3 months before the pre-study visit should not vary by more than 25% from the serum creatinine value determined at the pre-study visit
Show all 9Show fewer
- For healthy subjects:
- eGFR ≥ 90 mL/min/1.73m^2 determined from serum creatinine 2-14 days prior to dosing
- Healthy subjects with age-, weight- and gender- matched to renal impaired subjects
Who cannot join
- For all subjects:
- Febrile illness within 1 week before the start of the study
- History of severe allergies, non-allergic drug reactions, or multiple drug allergies
- Hypersensitivity to the investigational drug, the control agent and/ or to inactive constituents
- Regular daily consumption of more than 1/2 liter of usual beer or the equivalent quantity of approximately 20 g of alcohol in another form or more than 1 liter of xanthine-containing beverages or more than 10 cigarettes
- Positive testing in the drug screening
Show all 27Show fewer
- Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), human immune deficiency virus antibodies (anti-HIV 1+2)
- Donation of more than 100 mL of blood in the preceding 4 weeks or 500 mL in the preceding 3 months
- Relevant deviation from the normal range in clinical chemistry, hematology, coagulation or urinalysis as judged by the investigator For subjects with renal impairment
- Acute renal failure
- Acute nephritis
- Any organ transplant in the past 5 years
- Severe cerebrovascular or cardiac disorders, e.g. myocardial infarction less than 6 months prior to dosing, congestive heart failure of New York Heart Association grade III or IV, severe arrhythmia requiring anti-arrhythmic treatment
- Percutaneous transluminal coronary angioplasty or coronary artery bypass graft less than 6 months prior to dosing
- Diagnosed malignancy within the past 5 years
- Failure of any other major organ system other than the kidney
- Concomitant use of any medication except medications necessary for the treatment of diseases
- Diastolic BP >100 mmHg and/or systolic BP >180 mmHg
- Heart rate below 50 beats/min or above 100 beats/min at screening visit
- Significant uncorrected rhythm or conduction disturbances For healthy subjects
- Subjects with conspicuous findings in medical history or pre-study examination
- A history of relevant diseases of vital organs, of the central nervous system or other organs
- Excluded therapies (e.g. physiotherapy, acupuncture, etc.) from 1 week before admission to the ward (-01d)
- Use of medication within the 2 weeks preceding the study which could interfere with the investigational product
- Systolic BP below 100 mmHg or above 145 mmHg and Diastolic BP below 55 mmHg or above 95 mmHg
- Heart rate below 50 beats/min or above 100 beats/min
- Clinically relevant findings in the electrocardiogram (ECG)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Investigation of Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of BAY1021189 in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects Following a Single Oral Dose of 2.5 mg BAY1021189 in a Single-center, Non Randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification
Vericiguat (BAY1021189) is under development to treat heart failure, a condition in in which the heart has trouble pumping blood through the body. Renal impairment which co-occurs in patients with heart failure is a common condition in which the kidneys are not filtering the blood as well as they should.
The goal of the study was to learn more about the safety of vericiguat (BAY1021189), how it was tolerated and the way the body absorbed, distributed and excreted the study dug given as a single oral dose of 2.5 mg tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight.
The participants stayed at the trial site for about 6 days. During this time, the doctors took blood and urine samples and checked the participants' health. About 7-14 days after the participants took vericiguat (BAY1021189), the researchers checked the participants' health again and asked about any medical problems they had.
- Conditions
- Heart Failure
- Being tested
- Vericiguat (BAY1021189)
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vericiguat (BAY1021189)Drug
Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
| Study group | Role | What they receive |
|---|---|---|
| Patients with normal creatine clearance (CLCR) | Experimental | Subjects with renal impairment according to their medical history and estimated glomerular filtration rate (eGFR) at screening but had normal creatinine clearance at the pre-profile day (-01day) Receives: Drug: Vericiguat (BAY1021189) |
| Normal renal function (Healthy subjects) | Experimental | Subjects with creatinine clearance at pre-profile day >80 ml/min Receives: Drug: Vericiguat (BAY1021189) |
| Mildly impaired renal function | Experimental | Subjects with creatinine clearance at pre-profile day in the range of 50-80 ml/min Receives: Drug: Vericiguat (BAY1021189) |
| Moderately impaired renal function | Experimental | Subjects with creatinine clearance at pre-profile day in the range of 30-<50 ml/min Receives: Drug: Vericiguat (BAY1021189) |
| Severely impaired renal function | Experimental | Subjects with creatinine clearance at pre-profile day <30 ml/min Receives: Drug: Vericiguat (BAY1021189) |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUC of vericiguat
Area under the concentration vs. time curve from zero to infinity after single dose administration
Measured: Up to 96 hours
Cmax of vericiguat
Maximum observed drug concentration in measured matrix after single dose administration
Measured: Up to 96 hours
AUC of vericiguat's metabolite M-1
Area under the concentration vs. time curve from zero to infinity after single dose administration
Measured: Up to 96 hours
Cmax of vericiguat's metabolite M-1
Maximum observed drug concentration in measured matrix after single dose administration
Measured: Up to 96 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2021
- Study start12 Jun 2014
- Primary completion22 Jan 2015
- Study completion22 Jan 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by BayerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 39 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bayer
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Merck Sharp & Dohme LLC
- Responsible party
- Sponsor
- Investigators
- Bayer Study Director, Study director, Bayer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04722484
- Sponsor's protocol ID
- 15813
- Other IDs
- 2013-004762-34
- Status last verified
- Jan 2021
- First submitted
- 21 Jan 2021
- Last updated
- 25 Jan 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of BAY1021189 in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects Following a Single Oral Dose of 2.5 mg BAY1021189 in a Single-center, Non Randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification
- ClinicalTrials.gov ID
- NCT04722484
- Acronym / sponsor ID
- 15813
- Conditions
- Heart Failure
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 39 participants (actual)
- Lead sponsor
- BayerIndustry (pharma, biotech, devices)
- Collaborators
- Merck Sharp & Dohme LLC
- Study start
- 12 Jun 2014 (actual)
- Primary completion
- 22 Jan 2015 (actual)
- Study completion
- 22 Jan 2015 (actual)
- First posted
- 25 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Vericiguat (BAY1021189) is under development to treat heart failure, a condition in in which the heart has trouble pumping blood through the body. Renal impairment which co-occurs in patients with heart failure is a common condition in which the kidneys are not filtering the blood as well as they should.
The goal of the study was to learn more about the safety of vericiguat (BAY1021189), how it was tolerated and the way the body absorbed, distributed and excreted the study dug given as a single oral dose of 2.5 mg tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight.
The participants stayed at the trial site for about 6 days. During this time, the doctors took blood and urine samples and checked the participants' health. About 7-14 days after the participants took vericiguat (BAY1021189), the researchers checked the participants' health again and asked about any medical problems they had.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Patients with normal creatine clearance (CLCR) | Experimental | Drug: Vericiguat (BAY1021189)Subjects with renal impairment according to their medical history and estimated glomerular filtration rate (eGFR) at screening but had normal creatinine clearance at the pre-profile day (-01day) |
| Normal renal function (Healthy subjects) | Experimental | Drug: Vericiguat (BAY1021189)Subjects with creatinine clearance at pre-profile day >80 ml/min |
| Mildly impaired renal function | Experimental | Drug: Vericiguat (BAY1021189)Subjects with creatinine clearance at pre-profile day in the range of 50-80 ml/min |
| Moderately impaired renal function | Experimental | Drug: Vericiguat (BAY1021189)Subjects with creatinine clearance at pre-profile day in the range of 30-<50 ml/min |
| Severely impaired renal function | Experimental | Drug: Vericiguat (BAY1021189)Subjects with creatinine clearance at pre-profile day <30 ml/min |
Who may qualify
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Aged between 18 and 79 years (inclusive) with body mass index 18 to 34 kg/m^2 (both inclusive)
- Women without childbearing potential; women of childbearing potential only if the pregnancy test was negative and a combination of condoms with a safe and highly effective contraception method was granted
- With an estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73m^2 determined from a serum creatinine control 2-14 days prior to dosing
- Stable renal disease, i.e. a serum creatinine value determined at least 3 months before the pre-study visit should not vary by more than 25% from the serum creatinine value determined at the pre-study visit
- eGFR ≥ 90 mL/min/1.73m^2 determined from serum creatinine 2-14 days prior to dosing
Key exclusion criteria (27 listed)
- Febrile illness within 1 week before the start of the study
- History of severe allergies, non-allergic drug reactions, or multiple drug allergies
- Hypersensitivity to the investigational drug, the control agent and/ or to inactive constituents
- Regular daily consumption of more than 1/2 liter of usual beer or the equivalent quantity of approximately 20 g of alcohol in another form or more than 1 liter of xanthine-containing beverages or more than 10 cigarettes
- Positive testing in the drug screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vericiguat (BAY1021189)Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet) | Drug | Mildly impaired renal function, Moderately impaired renal function, Normal renal function (Healthy subjects), Patients with normal creatine clearance (CLCR), Severely impaired renal function |
Primary outcome
AUC of vericiguat
Time frame: Up to 96 hours
Area under the concentration vs. time curve from zero to infinity after single dose administration
Cmax of vericiguat
Time frame: Up to 96 hours
Maximum observed drug concentration in measured matrix after single dose administration
AUC of vericiguat's metabolite M-1
Time frame: Up to 96 hours
Area under the concentration vs. time curve from zero to infinity after single dose administration
Cmax of vericiguat's metabolite M-1
Time frame: Up to 96 hours
Maximum observed drug concentration in measured matrix after single dose administration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2021.
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bayer Study Director study director
Bayer
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Vericiguat (BAY1021189) in people with Heart Failure, run by Bayer at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AUC of vericiguat (time frame: Up to 96 hours). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2021.